Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • FDA approves Vosevi™ for the treatment of chronic Hepatitis C virus infection

    by
    • Optum Workers' Comp
    | Jul 20, 2017
    Tag Icon
    Medication Plans, FDA
    The U.S. Food and Drug Administration (FDA) has approved a new fixed-dose, combination medication Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.


  • First-time generic approved for Truvada®

    by
    • Optum Workers' Comp
    | Jun 29, 2017
    Tag Icon
    Generics, FDA
    The U.S. Food and Drug Administration (FDA) recently approved Teva’s AB-rated generic for Gilead’s Truvada® (emtricitabine/tenofovir disoproxil fumarate) 200 mg/300 mg oral tablet. This is the first time a generic has been approved for this medication. Truvada is a combination antiretroviral medication indicated for use in combination with other antiretroviral medications for the treatment of human immunodeficiency virus type-1 (HIV-1) infection in adults and pediatric patients weighing at least 17 kg (approximately 37.5 pounds), and in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.


  • Teva introduces generic Skelaxin®

    by
    • Optum Workers' Comp
    | Jun 22, 2017
    Tag Icon
    Generics
    Teva Pharmaceuticals announced it will be manufacturing a generic version of Skelaxin® (metaxalone) tablets. Skelaxin is a skeletal muscle relaxant used to relieve discomfort associated with acute, painful musculoskeletal conditions as an adjunctive therapy. Metaxalone is currently available in 400 mg and 800 mg tablets; however, Teva is only advertising the launch of 800 mg tablets. This new generic adds to a list of other previously released generic metaxalone tablets.


  • Medication recall for one lot of Eliquis® (apixaban)

    by
    • Optum Workers' Comp
    | Jun 15, 2017
    Tag Icon
    Medication Recall
    Bristol-Myers Squibb Company announced a consumer-level recall on one lot of Eliquis® (apixaban) 5 mg tablets were mislabeled due to a complaint from a customer who found Eliquis 2.5 mg tablets in their bottle that should have contained 5 mg tablets.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.